Scienture Holdings, Inc.
$ 0.38
3.33%
24 Feb - close price
- Market Cap 15,114,700 USD
- Current Price $ 0.38
- High / Low $ 0.39 / 0.38
- Stock P/E 0.50
- Book Value 3.57
- EPS 0.75
- Next Earning Report 2026-03-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.24 %
- 52 Week High 3.61
- 52 Week Low 0.37
About
Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm dedicated to the advancement of therapeutic solutions for neurological disorders. Utilizing state-of-the-art technology and a highly skilled research team, the company is committed to addressing unmet medical needs and enhancing patient outcomes through its innovative drug development pipeline. With a strong focus on scientific excellence and regulatory adherence, Scienture is strategically positioned for substantial growth in the expanding healthcare sector. The company's emphasis on partnerships and collaborations further amplifies its research capabilities, allowing it to significantly contribute to global health improvements.
Analyst Target Price
N/A
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-04-21 | 2025-03-26 | 2024-11-29 | 2024-07-22 | 2024-04-24 | 2024-03-25 | 2023-10-25 | 2023-07-24 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -0.19 | -0.48 | -0.3251 | -0.79 | -1.3411 | -1.304 | 20.4928 | -12.9457 | -4.571 | -2.8991 | -0.07 | -1.5 |
| Estimated EPS | 0 | None | None | 0.38 | None | None | None | None | None | -0.45 | -0.02 | -0.2733 |
| Surprise | -0.19 | 0 | 0 | -1.17 | 0 | 0 | 0 | 0 | 0 | -2.4491 | -0.05 | -1.2267 |
| Surprise Percentage | None% | None% | None% | -307.8947% | None% | None% | None% | None% | None% | -544.2444% | -250% | -448.8474% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jul 2024 | Mar 2024 | |
|---|---|---|
| Payment Date | 2024-07-24 | 2024-03-22 |
| Amount | $1.5 | $8.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCNX
2026-02-04 00:29:20
Scienture Holdings, Inc. (NASDAQ:SCNX) has announced expanded market access for its liquid losartan formulation, ARBLI, through new rebate and GPO agreements, and formulary inclusion covering over 100 million lives. The company also confirmed the launch of its naloxone nasal spray, REZENOPY, for Q2 2026, targeting the opioid overdose emergency market. Despite positive product developments and a strengthened financial position with $7.0 million in cash, Scienture remains unprofitable with a diluted EPS of -$1.57.
2026-02-03 18:28:52
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) provided a commercial update on ARBLI™ (losartan potassium) oral suspension, the first FDA-approved ready-to-use oral liquid formulation of losartan. The company highlighted accelerating access and revenue growth for ARBLI™ and reaffirmed the commercial launch timeline for REZENOPY™, a life-saving opioid overdose emergency treatment, in Q2 2026. Scienture also reported significant balance sheet improvement in Q4 2025, with approximately $7.0 million in cash.
2026-02-03 13:28:58
SCIENTURE (NASDAQ: SCNX) provided a commercial update on its FDA-approved oral suspension ARBLI and its upcoming overdose treatment REZENOPY, reporting significant advancements in market access and distribution. The company secured PBM-led GPO rebates and institutional GPO agreements, expanding ARBLI's reach to over 100 million covered lives. SCIENTURE reaffirmed REZENOPY's commercial launch in Q2 2026 and reported a strengthened balance sheet with approximately $7.0 million in cash after debt reduction.
2026-02-03 13:28:58
Scienture Holdings, Inc. has announced expanded market access for its liquid losartan formulation, ARBLI, through new PBM rebate agreements and GPO contracts, covering over 100 million lives. The company also confirmed its plans to launch REZENOPY, a naloxone nasal spray for opioid overdose, in the second quarter of 2026, marking its second U.S. market entry. Despite a strong gross profit margin of 88.48% and an optimized capital structure with $7.0 million in cash, Scienture remains unprofitable with a diluted EPS of -$1.57.
2026-01-15 10:27:10
SCIENTURE Holdings, Inc. announced the issuance of a U.S. patent for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which is now Orange Book-listable. This patent strengthens the intellectual property protection for REZENOPY™, the highest-dosage naloxone HCl nasal spray approved by the FDA, and supports Scienture's long-term commercial strategy in the growing U.S. naloxone market. The product is intended for emergency treatment of opioid overdose and is manufactured by Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P.
2026-01-15 09:27:56
Scienture Holdings' partner, Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P., has been issued a U.S. patent for Rezenopy (naloxone HCl) Nasal Spray 10 mg, the highest-dosage naloxone spray approved by the FDA for opioid overdose. Scienture LLC holds exclusive U.S. commercialization rights for Rezenopy, and the new patent is eligible for Orange Book listing, potentially offering additional intellectual property protection. This development comes as Scienture reported significant revenue growth and expanding access for another product, Arbli.
